Published by Iain Gilbert on 2nd March 2020
(Sharecast News) - Gilead Sciences has entered into a definitive agreement to acquire clinical-stage immuno-oncology company Forty Seven for approximately $4.9bn.
URL: http://www.digitallook.com/dl/news/story/30322921/...